Life Sciences

Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.



Sign up for a 7-day FREE trial today!



Latest News in Life Sciences

  • July 22, 2026

    Trump Says 100% Tariff On Generic Drugs Coming In 2028

    Generic drugs imported into the U.S. will be hit with a tariff of 100% in 2028 and 200% in later years in an attempt to drive manufacturing into the country, President Donald Trump said on social media.

  • July 21, 2026

    DC Circ. Affirms HHS Authority Over 340B Rebate Plans

    The D.C. Circuit on Tuesday upheld a lower court's finding that U.S. Department of Health and Human Services has the authority to block or approve drugmakers' efforts to implement rebates instead of discounts under the 340B drug-pricing program.

  • July 21, 2026

    Economist Concedes Opioid Stats' Limits In Albertsons Trial

    Despite testifying that Albertsons pharmacy records suggest some opioids dispensed in Washington state had "red flags" for potential diversion from legitimate use, an economist for the Evergreen State conceded Tuesday that he can't point to "even a single pill dispensed by Albertsons" that was actually improperly diverted. 

  • July 21, 2026

    Full Fed. Circ. Won't Review Apple's ITC Loss Against Masimo

    The full slate of Federal Circuit judges will not reconsider a panel's determination that Apple has infringed Masimo Corp.'s blood oxygen monitor patents in a high-profile case that led to some Apple Watch imports being banned.

  • July 21, 2026

    Class Cert. In Avandia MDL Undone For Lacking Stats

    The Third Circuit undid class certification for a group of health plans claiming GlaxoSmithKline deceptively marketed its diabetes drug Avandia, with a panel majority ruling Tuesday the plans needed stronger statistical analysis to show links between the marketing, the revelation of side effects and a drop in sales.

See more Life Sciences news

Life Sciences

Areas of Coverage

  • AGENCIES
  • U.S. Consumer Product Safety Commission
  • U.S. Food and Drug Administration
  • U.S. Patent and Trademark Office
  • U.S. International Trade Commission
  • POLICY & REGULATION
  • Affordable Care Act
  • Federal Food, Drug, and Cosmetic Act
  • Antitrust and consumer protection controls
  • Drug and medical device lobbying
  • State and international life sciences legislation and regulation
  • ENFORCEMENT
  • Drug and medical device recalls
  • Drug safety actions
  • Pay-for-delay investigations
  • Merger reviews
  • LITIGATION
  • Patent disputes, including
  • Abbreviated New Drug Application litigation
  • Section 301 cases
  • Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
  • Consumer litigation and class actions
  • Fraud and compliance suits
  • Antitrust disputes
  • Labor and employment suits
  • Shareholder and corporate governance disputes
  • Bankruptcy proceedings
  • TRANSACTIONS
  • Mergers, acquisitions, and joint ventures
  • Share buybacks and stock splits
  • Private equity deals
  • Patent-licensing agreements
  • PROFILES
  • Personnel moves
  • Profiles of life sciences practice groups

Readership

  • Life sciences lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the drug, biotechnology, and medical device industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals